News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Nov 20, 2018

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration

Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+
Nov 19, 2018

Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -
Nov 12, 2018

Astellas Appoints Eloiza Domingo-Snyder to Head of Diversity and Inclusion
- Photos 1
Oct 9, 2018

Astellas Details Progress and Commitment to Patients and the Community in the Company's Americas 2017 Corporate Social Responsibility Report Card
- Photos 1
Oct 4, 2018

Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer Congress

Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
- Photos 1
Sep 25, 2018

Working Mother Magazine names Astellas among 100 best companies in the US across all industries

Astellas ranked in recognition of its commitment and support for working mothers
Sep 24, 2018

Astellas Farma Brasil named one of the best companies to work for in Brazil

Astellas recognized by Great Place to Work® Institute
Sep 24, 2018

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)
Sep 21, 2018

Astellas Oncology Announces C3 Prize® Celebrity Partnership and Category Winners

Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
Sep 18, 2018

Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US
- Photos 1
Sep 14, 2018

Astellas Named a PM360 Trailblazer 2018 "Company of the Year"

--Additional marketing award received for Best Video/TV Campaign--
- Photos 1
Sep 13, 2018

More than 800 Astellas Employees Volunteer for 16 Community Organizations as Part of Ninth Annual Changing Tomorrow Day
- Photos 3
Sep 12, 2018

Astellas Announces Launch of "What's Next Sweepstakes" with Laila Ali

Winner Will Attend Live Taping of ABC's "Dancing with the Stars"
Aug 23, 2018

Astellas Appoints Shontelle Dodson to Senior Vice President Health Systems
- Photos 1
Aug 23, 2018

Astellas Promotes Rodrigo Fernandez to Vice President, Latin America
- Photos 1
Aug 22, 2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials
Aug 16, 2018

Astellas Promotes David Abbott to National Vice President Key Account Management
- Photos 1
Aug 10, 2018

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma
Aug 3, 2018

Astellas Statement on U.S. Drug Pricing
Jul 23, 2018

Astellas Americas Announces Leadership Changes in Medical Affairs and Corporate Communications

Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications
- Photos 3
Jul 13, 2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
Jul 9, 2018

Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-
Jun 19, 2018

Astellas Employees at National Sales Forum Support Five Anaheim-Area Non-Profits

Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations
- Video 1
- Photos 2
Jun 8, 2018

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas
- Photos 1
Jun 3, 2018

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products